Clinical Study

A Phase III Randomized Trial Of Blinatumomab For Newly Diagnosed Bcr-Abl Negative B Lineage Acute Lymphoblastic Leukemia In Adults

Posted Date: May 15, 2019

  • Investigator: Stephen Medlin
  • Specialties:
  • Type of Study: Drug

This study in being done to determine what affects (good and bad) the therapy blinatumomab has on your type of cancer (BCR/ABL negative ALL). This new therapy will be added to what has traditionally been used to treat your specific sub-type of ALL. Studies are being done in ALL and other blood cance

Criteria:

To Qualify For This Study You Must Have Been Recently Diagnosed With A Subtype Of Acute Lymphoblasti

Keywords:

E1910, Leukemia, Negative B Lineage , All, Cancer

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.